JP2017529841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529841A5 JP2017529841A5 JP2017515087A JP2017515087A JP2017529841A5 JP 2017529841 A5 JP2017529841 A5 JP 2017529841A5 JP 2017515087 A JP2017515087 A JP 2017515087A JP 2017515087 A JP2017515087 A JP 2017515087A JP 2017529841 A5 JP2017529841 A5 JP 2017529841A5
- Authority
- JP
- Japan
- Prior art keywords
- region gene
- constant region
- car
- genetically modified
- locus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 219
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 154
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 102
- 241000283984 Rodentia Species 0.000 claims description 84
- 108091008874 T cell receptors Proteins 0.000 claims description 75
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 75
- 210000004027 cell Anatomy 0.000 claims description 73
- 229920001184 polypeptide Polymers 0.000 claims description 64
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 64
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 41
- 150000007523 nucleic acids Chemical group 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 31
- 108060003951 Immunoglobulin Proteins 0.000 claims description 29
- 102000018358 immunoglobulin Human genes 0.000 claims description 29
- 241000894007 species Species 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 230000001086 cytosolic effect Effects 0.000 claims description 18
- 102000043131 MHC class II family Human genes 0.000 claims description 15
- 108091054438 MHC class II family Proteins 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108010050568 HLA-DM antigens Proteins 0.000 claims description 6
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 claims description 5
- 238000012239 gene modification Methods 0.000 claims description 5
- 230000005017 genetic modification Effects 0.000 claims description 5
- 235000013617 genetically modified food Nutrition 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 3
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 3
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 3
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims description 3
- 102100033079 HLA class II histocompatibility antigen, DM alpha chain Human genes 0.000 claims description 3
- 102100031258 HLA class II histocompatibility antigen, DM beta chain Human genes 0.000 claims description 3
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims description 3
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 claims description 3
- 102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 claims description 3
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 claims description 3
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 3
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 3
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 3
- 108010041384 HLA-DPA antigen Proteins 0.000 claims description 3
- 108010086786 HLA-DQA1 antigen Proteins 0.000 claims description 3
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims description 3
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 3
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 3
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims description 3
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims description 3
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 claims description 3
- 102000047279 human B2M Human genes 0.000 claims description 3
- 108010024941 iodothyronine deiodinase type II Proteins 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 2
- -1 HLA-DPB Proteins 0.000 description 2
- 108010067148 HLA-DQbeta antigen Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052947P | 2014-09-19 | 2014-09-19 | |
| US201462052901P | 2014-09-19 | 2014-09-19 | |
| US62/052,901 | 2014-09-19 | ||
| US62/052,947 | 2014-09-19 | ||
| US201462076836P | 2014-11-07 | 2014-11-07 | |
| US62/076,836 | 2014-11-07 | ||
| US201462094603P | 2014-12-19 | 2014-12-19 | |
| US62/094,603 | 2014-12-19 | ||
| US201562167650P | 2015-05-28 | 2015-05-28 | |
| US62/167,650 | 2015-05-28 | ||
| PCT/US2015/050975 WO2016044745A1 (en) | 2014-09-19 | 2015-09-18 | Chimeric antigen receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529841A JP2017529841A (ja) | 2017-10-12 |
| JP2017529841A5 true JP2017529841A5 (enExample) | 2018-10-25 |
Family
ID=54261082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515087A Pending JP2017529841A (ja) | 2014-09-19 | 2015-09-18 | キメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160081314A1 (enExample) |
| EP (1) | EP3193592A1 (enExample) |
| JP (1) | JP2017529841A (enExample) |
| KR (1) | KR20170083534A (enExample) |
| CN (1) | CN107072184A (enExample) |
| AU (1) | AU2015317370A1 (enExample) |
| BR (1) | BR112017005245A2 (enExample) |
| CA (1) | CA2959428A1 (enExample) |
| IL (1) | IL250536A0 (enExample) |
| MX (1) | MX2017003640A (enExample) |
| RU (1) | RU2017113134A (enExample) |
| SG (1) | SG11201701040XA (enExample) |
| WO (1) | WO2016044745A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150064153A1 (en) | 2013-03-15 | 2015-03-05 | The Trustees Of Princeton University | High efficiency microfluidic purification of stem cells to improve transplants |
| EP3608022A1 (en) | 2013-03-15 | 2020-02-12 | The Trustees of Princeton University | Methods and devices for high throughput purification |
| CN110186835B (zh) | 2013-03-15 | 2022-05-31 | Gpb科学有限公司 | 颗粒的片上微流体处理 |
| EP3241561B1 (en) * | 2014-03-05 | 2025-04-30 | Autolus Limited | Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2 |
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| FR3029449B1 (fr) * | 2014-12-03 | 2017-10-13 | Pole De Plasturgie De Lest | Dispositif de moulage pour la fabrication de pieces en materiau composite a partir de resine polymere liquide. |
| BR112017013104A2 (pt) * | 2014-12-19 | 2018-05-15 | Regeneron Pharma | métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano. |
| DE112016002056T5 (de) | 2015-05-06 | 2018-02-08 | Snipr Technologies Limited | Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen |
| US10976232B2 (en) | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
| EP4108255A1 (en) | 2015-10-05 | 2022-12-28 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| AU2016333886B2 (en) | 2015-10-05 | 2020-10-08 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| PE20190356A1 (es) | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| PL3436079T3 (pl) | 2016-04-01 | 2021-12-20 | Kite Pharma, Inc. | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania |
| US10689450B2 (en) | 2016-04-01 | 2020-06-23 | Kite Pharma, Inc | BCMA binding molecules and methods of use thereof |
| CA3020923A1 (en) | 2016-04-15 | 2017-10-19 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| IL263160B2 (en) * | 2016-06-03 | 2024-01-01 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| WO2018011573A1 (en) * | 2016-07-12 | 2018-01-18 | Kymab Limited | Animals, cells, ligands, polypeptides & methods |
| JP7500195B2 (ja) * | 2016-08-23 | 2024-06-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
| WO2018075586A1 (en) * | 2016-10-18 | 2018-04-26 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof |
| CA3044682A1 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| EP4653464A2 (en) | 2016-12-23 | 2025-11-26 | MacroGenics, Inc. | Adam9-binding molecules, and methods of use thereof |
| EP3579877A4 (en) * | 2017-02-09 | 2020-12-09 | The Regents of The University of California | CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE |
| WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| WO2018184558A1 (zh) * | 2017-04-05 | 2018-10-11 | 凯惠科技发展(上海)有限公司 | 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用 |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| AU2018292526A1 (en) | 2017-06-30 | 2020-01-16 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
| KR102780441B1 (ko) | 2017-07-31 | 2025-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도 |
| KR20200033259A (ko) | 2017-07-31 | 2020-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물 |
| CA3074495A1 (en) | 2017-09-01 | 2019-03-07 | Gpb Scientific, Llc | Methods for preparing therapeutically active cells using microfluidics |
| MA50185A (fr) | 2017-09-22 | 2020-07-29 | Wuxi Biologics Ireland Ltd | Nouveaux complexes polypeptidiques cd3/cd19 bispécifiques |
| MY202919A (en) * | 2017-09-22 | 2024-05-29 | Wuxi Biologics Ireland Ltd | Novel bispecific polypeptide complexes |
| EP3585162B1 (en) | 2017-09-29 | 2023-08-30 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| KR102503130B1 (ko) * | 2017-10-27 | 2023-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| WO2019161271A1 (en) | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| CN111885915B (zh) | 2018-03-19 | 2023-04-28 | 瑞泽恩制药公司 | 使用crispr/cas系统对动物进行转录调制 |
| SMT202500038T1 (it) * | 2018-03-24 | 2025-03-12 | Regeneron Pharma | Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CN108424931A (zh) * | 2018-03-29 | 2018-08-21 | 内蒙古大学 | CRISPR/Cas9技术介导山羊VEGF基因定点整合的方法 |
| WO2019200122A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| IL283734B2 (en) | 2018-12-12 | 2025-03-01 | Kite Pharma Inc | Chimeric antigen receptors and CAR-T cells and methods of use |
| TW202039543A (zh) * | 2018-12-27 | 2020-11-01 | 國立大學法人京都大學 | Ｔ細胞受體的變體 |
| AU2020253532B2 (en) | 2019-04-04 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| SG11202111256XA (en) | 2019-06-07 | 2021-11-29 | Regeneron Pharma | Non-human animals comprising a humanized albumin locus |
| CA3145857A1 (en) * | 2019-07-03 | 2021-01-07 | Regeneron Pharmaceuticals, Inc. | Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof |
| EP3999081A1 (en) | 2019-07-18 | 2022-05-25 | GPB Scientific, Inc. | Ordered processing of blood products to produce therapeutically active cells |
| WO2021050948A1 (en) * | 2019-09-12 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN115209996B (zh) | 2019-12-28 | 2025-09-05 | 日本瑞翁株式会社 | 用于处理颗粒和细胞的微流体盒 |
| JP2023511626A (ja) | 2020-01-28 | 2023-03-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｐｎｐｌａ３遺伝子座を含む非ヒト動物および使用方法 |
| WO2021156277A1 (en) * | 2020-02-04 | 2021-08-12 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens |
| CN111320703A (zh) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | 靶向cd22的嵌合抗原受体及其应用 |
| WO2021190580A1 (en) * | 2020-03-26 | 2021-09-30 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific polypeptide complexes, compositions, and methods of preparation and use |
| CN114746152A (zh) * | 2020-08-23 | 2022-07-12 | 应用干细胞有限公司 | Hla-f修饰的细胞和方法 |
| CN117615786A (zh) * | 2021-05-07 | 2024-02-27 | 森蒂生物科学公司 | 嵌合抗原受体及其使用方法 |
| EP4215042A1 (en) * | 2022-01-21 | 2023-07-26 | Max-Delbrück-Centrum für Molekulare Medizin | A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereof |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| CN116138212B (zh) * | 2023-01-11 | 2024-03-05 | 江苏省中医院 | 一种制备细胞因子释放综合征小鼠模型的方法及应用 |
| CN118460446B (zh) * | 2024-07-12 | 2024-11-15 | 内蒙古自治区农牧业科学院 | 一种支原体突变株及其制备方法与应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| JPS6463394A (en) * | 1987-09-04 | 1989-03-09 | Kyowa Hakko Kogyo Kk | Novel chimera polypeptide |
| IL86278A (en) * | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6045796A (en) | 1992-12-17 | 2000-04-04 | Anergen, Inc. | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
| US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869270A (en) | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US7001614B2 (en) | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US7112338B2 (en) | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| WO2004058278A1 (en) | 2002-12-16 | 2004-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant vaccine viruses expressing il-15 and methods of using the same |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| US8218805B2 (en) | 2003-10-11 | 2012-07-10 | Charles Hornback | Wireless speaker system for use with ceiling fans |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| DK1709081T3 (da) | 2004-01-16 | 2011-06-06 | Regeneron Pharma | Fusionspolypeptider, der kan aktivere receptorer |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| WO2007001457A2 (en) | 2004-11-12 | 2007-01-04 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| WO2006076594A2 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| US20070190063A1 (en) | 2005-08-19 | 2007-08-16 | Bahjat Keith S | Antibody-mediated enhancement of immune response |
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| EP2505058A1 (en) | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| WO2009052328A1 (en) | 2007-10-18 | 2009-04-23 | Bn Immunotherapeutics Inc. | Use of mva to treat prostate cancer |
| US8225343B2 (en) | 2008-01-11 | 2012-07-17 | Sony Computer Entertainment America Llc | Gesture cataloging and recognition |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| RU2012145183A (ru) | 2010-03-29 | 2014-05-10 | Займворкс, Инк. | Антитела с повышенной или пониженной эффекторной функцией |
| SI2480676T1 (sl) | 2010-06-22 | 2016-10-28 | Regeneron Pharmaceuticals, Inc. | Hibridna mišja lahka veriga |
| US8539547B2 (en) | 2010-08-18 | 2013-09-17 | Certes Networks, Inc. | Policy selector representation for fast retrieval |
| DK2813573T1 (da) | 2011-02-25 | 2015-01-12 | Regeneron Pharma | ADAM6 mus |
| JP5893258B2 (ja) | 2011-03-31 | 2016-03-23 | フェリカネットワークス株式会社 | 情報処理装置および方法、並びにプログラム |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| SG10201510056SA (en) | 2011-10-28 | 2016-01-28 | Regeneron Pharma | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
| CN104011071B (zh) | 2011-10-28 | 2017-11-07 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| KR102295746B1 (ko) | 2011-10-28 | 2021-09-01 | 리제너론 파아마슈티컬스, 인크. | 유전자 변형된 주요 조직적합성 복합체 마우스 |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| KR102052774B1 (ko) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| US9547499B2 (en) | 2011-12-09 | 2017-01-17 | Microsoft Technology Licensing, Llc | Device configuration with cached pre-assembled driver state |
| WO2013126726A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| JP5920830B2 (ja) | 2012-09-28 | 2016-05-18 | シスメックス株式会社 | 試料調製装置および細胞分析装置 |
| CA2900832A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| RS57582B1 (sr) | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca |
| JP6444321B2 (ja) | 2013-02-22 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化主要組織適合性遺伝子複合体を発現するマウス |
-
2015
- 2015-09-18 KR KR1020177010023A patent/KR20170083534A/ko not_active Withdrawn
- 2015-09-18 RU RU2017113134A patent/RU2017113134A/ru not_active Application Discontinuation
- 2015-09-18 BR BR112017005245A patent/BR112017005245A2/pt not_active Application Discontinuation
- 2015-09-18 WO PCT/US2015/050975 patent/WO2016044745A1/en not_active Ceased
- 2015-09-18 US US14/858,597 patent/US20160081314A1/en not_active Abandoned
- 2015-09-18 JP JP2017515087A patent/JP2017529841A/ja active Pending
- 2015-09-18 AU AU2015317370A patent/AU2015317370A1/en not_active Abandoned
- 2015-09-18 MX MX2017003640A patent/MX2017003640A/es unknown
- 2015-09-18 EP EP15775854.1A patent/EP3193592A1/en not_active Withdrawn
- 2015-09-18 CN CN201580050602.0A patent/CN107072184A/zh active Pending
- 2015-09-18 SG SG11201701040XA patent/SG11201701040XA/en unknown
- 2015-09-18 CA CA2959428A patent/CA2959428A1/en not_active Abandoned
-
2017
- 2017-02-09 IL IL250536A patent/IL250536A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529841A5 (enExample) | ||
| RU2017113134A (ru) | Химерные антигенные рецепторы | |
| Castro et al. | T cell diversity and TcR repertoires in teleost fish | |
| JP7591094B2 (ja) | ヒト化ｃｄ３複合体を発現する非ヒト動物 | |
| JP6866409B2 (ja) | 遺伝子改変された主要組織適合複合体マウス | |
| KR102148387B1 (ko) | 유전자 변형된 ｔ 세포 수용체 마우스 | |
| FI3772927T3 (fi) | Geneettisesti muunneltuja hiiriä tai rottia terapeuttisten vasta-aineiden tuottamiseen peptidi-MHC-komplekseja vastaan, niiden valmistusmenetelmiä ja käyttötarkoituksia | |
| JP2022140609A (ja) | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 | |
| JP2018513683A5 (enExample) | ||
| JP2016507247A5 (enExample) | ||
| JP2014532411A5 (enExample) | ||
| JP2015519076A5 (enExample) | ||
| JP2017509355A5 (enExample) | ||
| Sonntag et al. | Chronic graft-versus-host-disease in CD34+-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease | |
| JP2016512034A5 (enExample) | ||
| HRP20201403T1 (hr) | Neljudske životinje koje imaju genetski modificiran lokus imunoglobulinskog lambda lakog lanca | |
| SI2840892T1 (en) | Animals other than humans with modified immunoglobulin heavy chain sequences | |
| JP2018512151A5 (enExample) | ||
| JP2014110814A5 (enExample) | ||
| Petersdorf | Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation | |
| Colantonio et al. | KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif | |
| Karaki et al. | HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies | |
| Bimber et al. | The killer‐cell immunoglobulin‐like receptors of macaques | |
| Horwitz et al. | T-cell receptors from virus-specific cytotoxic T lymphocytes recognizing a single immunodominant nine-amino-acid viral epitope show marked diversity | |
| Ru et al. | Development of a humanized HLA-A2. 1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein |